This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014…
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the…
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at…
MORRISTOWN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- The Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug…
MARKHAM, Ontario, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Dr. Pardeep Nijhawan (“Dr. Nijhawan”) announces that as a result of grants…
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on September 12,…
LUND, SWEDEN / ACCESSWIRE / September 14, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today presented data from…
Comprehensive Smartwatch Reference Platform to Include Key Hardware and Software Components, Including Industry-leading Masimo Biosensing Capabilities IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ:…
Finding of Contempt is an Extraordinary and Severe Remedy Court Finds Politan’s False Statements Improperly Influenced ISS and Glass Lewis…
DUBLIN--(BUSINESS WIRE)--The "US Digital Health Market (by Technology & Component): Insights & Forecast (2024-2028)" report has been added to ResearchAndMarkets.com's…